162 related articles for article (PubMed ID: 28697111)
1. Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
Spencer RJ; Hacker KE; Griggs JJ; Rice LW; Reynolds RK; Uppal S
Obstet Gynecol; 2017 Aug; 130(2):305-314. PubMed ID: 28697111
[TBL] [Abstract][Full Text] [Related]
2. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
3. Hospital Readmission as a Poor Measure of Quality in Ovarian Cancer Surgery.
Uppal S; Spencer RJ; Rice LW; Del Carmen MG; Reynolds RK; Griggs JJ
Obstet Gynecol; 2018 Jul; 132(1):126-136. PubMed ID: 29889756
[TBL] [Abstract][Full Text] [Related]
4. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
[TBL] [Abstract][Full Text] [Related]
5. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
7. Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
Barber EL; Dusetzina SB; Stitzenberg KB; Rossi EC; Gehrig PA; Boggess JF; Garrett JM
Gynecol Oncol; 2017 Jun; 145(3):500-507. PubMed ID: 28366545
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
9. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.
Schrag D; Earle C; Xu F; Panageas KS; Yabroff KR; Bristow RE; Trimble EL; Warren JL
J Natl Cancer Inst; 2006 Feb; 98(3):163-71. PubMed ID: 16449676
[TBL] [Abstract][Full Text] [Related]
10. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
Cowan RA; Tseng J; Ali N; Dearie H; Murthy V; Gennarelli RL; Iasonos A; Abu-Rustum NR; Chi DS; Long Roche KC; Brown CL
Gynecol Oncol; 2018 Apr; 149(1):43-48. PubMed ID: 29605049
[TBL] [Abstract][Full Text] [Related]
11. Modifiable risk factors associated with long-term survival in women with serous ovarian cancer: a National Cancer Database study.
Frost AS; Smith AJB; Fader AN; Wethington SL
Int J Gynecol Cancer; 2022 Jun; 32(6):769-780. PubMed ID: 35459709
[TBL] [Abstract][Full Text] [Related]
12. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
13. Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.
Katsnelson M; Hwang WT; Tahirovic E; Rubin SC; Tanyi JL
J Obstet Gynaecol; 2018 Apr; 38(3):395-401. PubMed ID: 29385863
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
Melamed A; Nitecki R; Boruta DM; Del Carmen MG; Clark RM; Growdon WB; Goodman A; Schorge JO; Rauh-Hain JA
Obstet Gynecol; 2017 May; 129(5):861-869. PubMed ID: 28383367
[TBL] [Abstract][Full Text] [Related]
15. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
17. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
Elias KM; Kang S; Liu X; Horowitz NS; Berkowitz RS; Frendl G
Ann Surg Oncol; 2015 Apr; 22(4):1341-8. PubMed ID: 25287437
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
19. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
Lydiksen L; Jensen-Fangel S; Blaakaer J
Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
